Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Rational design of anti-GITR-based combination immunotherapy

Open access
Zappasodi, Roberta, Sirard, Cynthia, Li, Yanyun, Budhu, Sadna, Abu-Akeel, Mohsen, Liu, Cailian, Yang, Xia, Zhong, Hong, Newman, Walter, Qi, Jingjing, Wong, Phillip, Schaer, David, Koon, Henry, Velcheti, Vamsidhar, Hellmann, Matthew D., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Merghoub, Taha · 2019 · Nature Medicine

Abstract

Modulating T cell homeostatic mechanisms with checkpoint blockade can efficiently promote endogenous anti-tumor T cell responses1–11. However, many patients still do not benefit from checkpoint blockade12, highlighting the need for targeting of alternative immune pathways13. Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is an attractive target for immunotherapy, owing to its capacity to promote effector T cell (Teff) functions14,15 and hamper regulatory T cell (Treg) suppression16–20. On the basis of the potent preclinical anti-tumor activity of agonist anti-GITR antibodies, reported by us and others16,21,22, we initiated the first in-human phase 1 trial of GITR agonism with the anti-GITR antibody TRX518 (NCT01239134). Here, we report the safety profile and immune effects of TRX518 monotherapy in patients with advanced cancer and provide mechanistic preclinical evidence to rationally combine GITR agonism with checkpoint blockade in future clinical trials. We demonstrate that TRX518 reduces circulating and intratumoral Treg cells to similar extents, providing an easily assessable biomarker of anti-GITR activity. Despite Treg reductions and increased Teff:Treg ratios, substantial clinical responses were not seen. Similarly, in mice with advanced tumors, GITR agonism was not sufficient to activate cytolytic T cells due to persistent exhaustion. We demonstrate that T cell reinvigoration with PD-1 blockade can overcome resistance of advanced tumors to anti-GITR monotherapy. These findings led us to start investigating TRX518 with PD-1 pathway blockade in patients with advanced refractory tumors (NCT02628574). GITR agonism can be exploited in combination with checkpoint blockade to overcome immune refractoriness in solid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0420-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 227

Metadata

Authors
Zappasodi, R., Sirard, C., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., Wong, P., Schaer, D., Koon, H., Velcheti, V., Hellmann, M. D., Postow, M. A., Callahan, M. K., Wolchok, J. D., & Merghoub, T.
Venue
Nature Medicine
Published
2019-04-29
Volume
25
Issue
5
Pages
759-766
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2940591955
Cited by
227
References
14
FWCI
13.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rational design of anti-GITR-based combination immunotherapy. https://app.cochat.ai/papers/10.1038/s41591-019-0420-8
The paper
Zappasodi, R., Sirard, C., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., Wong, P., Schaer, D., Koon, H., Velcheti, V., Hellmann, M. D., Postow, M. A., Callahan, M. K., Wolchok, J. D., & Merghoub, T. (2019). Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. https://doi.org/10.1038/s41591-019-0420-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.